HRP20231749T1 - Imunogeni pripravak - Google Patents
Imunogeni pripravak Download PDFInfo
- Publication number
- HRP20231749T1 HRP20231749T1 HRP20231749TT HRP20231749T HRP20231749T1 HR P20231749 T1 HRP20231749 T1 HR P20231749T1 HR P20231749T T HRP20231749T T HR P20231749TT HR P20231749 T HRP20231749 T HR P20231749T HR P20231749 T1 HRP20231749 T1 HR P20231749T1
- Authority
- HR
- Croatia
- Prior art keywords
- fragment
- proximal end
- toxin
- polypeptide according
- repeat
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims 4
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 7
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 5
- 101710182532 Toxin a Proteins 0.000 claims 5
- 241000193163 Clostridioides difficile Species 0.000 claims 3
- 101710182223 Toxin B Proteins 0.000 claims 3
- 108700022831 Clostridium difficile toxB Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (15)
1. Polipeptid koji sadrži prvi fragment i drugi fragment, naznačen time što
(i) prvi fragment je Clostridium difficile toksin A fragment ponavljajuće domene;
(ii) drugi fragment je Clostridium difficile_toxin B fragment ponavljajuće domene;
(iii) prvi fragment ima prvi proksimalni kraj;
(iv) drugi fragment ima drugi proksimalni kraj; i
pri čemu su prvi fragment i drugi fragment jedan uz drugi i gdje polipeptid izaziva antitijela koja neutraliziraju toksin A i toksin B i
pri čemu prvi proksimalni kraj nije unutar aminokiselina 1878-1940, 2012-2074, 2146-2208, 2258-2322, 2394-2456, 2507-2569 ili 2598-2660 toksina A i drugi proksimalni kraj je unutar aminokiselina 1834-1926 ili 1927-2057 toksina B, ali ne unutar aminokiselina 1881-1942 ili 2012-2057 toksina B.
2. Polipeptid prema zahtjevu 1 naznačen time što polipeptid izaziva zaštitni imunološki odgovor kod sisavca domaćina protiv sojeva C.difficile.
3. Polipeptid prema bilo kojem od zahtjeva 1-2 naznačen time što prvi fragment i/ili drugi fragment sadrži manje od 25%, 20%, 18% ili 15% alfa spiralne strukture.
4. Polipeptid prema bilo kojem prethodnom zahtjevu, naznačen time što prvi fragment i/ili drugi fragment sadrži više od 25%, 30%, 35%, 38% ili 40% strukture beta lista.
5. Polipeptid prema bilo kojem prethodnom zahtjevu naznačen time što je prvi proksimalni kraj unutar kratkog ponavljanja.
6. Polipeptid prema bilo kojem prethodnom zahtjevu naznačen time što je drugi proksimalni kraj unutar kratkog ponavljanja.
7. Polipeptid prema bilo kojem prethodnom zahtjevu naznačen time što prvi proksimalni kraj ne ometa dio kratkog ponavljanja-dugog ponavljanja-kratkog ponavljanja.
8. Polipeptid prema bilo kojem prethodnom zahtjevu naznačen time što drugi proksimalni kraj ne ometa dio kratkog ponavljanja-dugog ponavljanja-kratkog ponavljanja.
9. Polipeptid prema bilo kojem prethodnom zahtjevu naznačen time što prvi proksimalni kraj i drugi proksimalni kraj ne prekidaju dijelove kratkog ponavljanja-dugog ponavljanja-kratkog ponavljanja.
10. Polipeptid prema bilo kojem prethodnom zahtjevu naznačen time što je prvi proksimalni kraj unutar ponovljenog dijela VIII (aminokiseline 2645-2710) toksina A, izborno unutar aminokiselina 2700-2710 ili 2680-2690 toksina A.
11. Polipeptid prema bilo kojem prethodnom zahtjevu naznačen time što je drugi proksimalni kraj unutar aminokiselina 1860-1878, 1854-1876, izborno unutar aminokiselina 1960-1970, 1988-1998 ili 1867-1877 toksina B.
12. Polinukleotid koji kodira polipeptid prema bilo kojem od zahtjeva 1-11.
13. Imunogeni pripravak koji sadrži polipeptid prema bilo kojem od zahtjeva 1-11 i farmaceutski prihvatljivu pomoćnu tvar.
14. Imunogeni pripravak prema zahtjevu 13 nadalje sadrži adjuvans.
15. Imunogeni pripravak prema bilo kojem od zahtjeva 13-14 za uporabu u liječenju ili prevenciji bolesti C. difficile.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490734P | 2011-05-27 | 2011-05-27 | |
| US201161490707P | 2011-05-27 | 2011-05-27 | |
| US201161490716P | 2011-05-27 | 2011-05-27 | |
| EP19179871.9A EP3564378B1 (en) | 2011-05-27 | 2012-05-25 | Immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231749T1 true HRP20231749T1 (hr) | 2024-03-15 |
Family
ID=46168484
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231749TT HRP20231749T1 (hr) | 2011-05-27 | 2012-05-25 | Imunogeni pripravak |
| HRP20170094TT HRP20170094T1 (hr) | 2011-05-27 | 2017-01-20 | Imunogeni pripravak |
| HRP20180339TT HRP20180339T1 (hr) | 2011-05-27 | 2018-02-23 | Imunogeni pripravak |
| HRP20191291TT HRP20191291T1 (hr) | 2011-05-27 | 2019-07-17 | Imunogeni pripravak |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170094TT HRP20170094T1 (hr) | 2011-05-27 | 2017-01-20 | Imunogeni pripravak |
| HRP20180339TT HRP20180339T1 (hr) | 2011-05-27 | 2018-02-23 | Imunogeni pripravak |
| HRP20191291TT HRP20191291T1 (hr) | 2011-05-27 | 2019-07-17 | Imunogeni pripravak |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9290565B2 (hr) |
| EP (6) | EP3564378B1 (hr) |
| JP (3) | JP2014516532A (hr) |
| KR (1) | KR102014502B1 (hr) |
| CN (3) | CN107098977A (hr) |
| BR (2) | BR112013030396A2 (hr) |
| CA (2) | CA2837395C (hr) |
| CY (3) | CY1118599T1 (hr) |
| DK (4) | DK3138916T3 (hr) |
| EA (1) | EA030898B1 (hr) |
| ES (4) | ES2615737T3 (hr) |
| FI (1) | FI3564378T3 (hr) |
| HR (4) | HRP20231749T1 (hr) |
| HU (4) | HUE030823T2 (hr) |
| IL (1) | IL229529B2 (hr) |
| LT (4) | LT2714910T (hr) |
| ME (1) | ME02600B (hr) |
| MX (1) | MX346200B (hr) |
| PL (4) | PL2714911T3 (hr) |
| PT (4) | PT3138916T (hr) |
| RS (1) | RS55605B1 (hr) |
| SG (1) | SG195037A1 (hr) |
| SI (4) | SI3564378T1 (hr) |
| SM (1) | SMT201700110B (hr) |
| WO (3) | WO2012163811A1 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101907434B1 (ko) | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
| HRP20231631T1 (hr) | 2011-04-22 | 2024-03-15 | Wyeth Llc | Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci |
| SG11201402375VA (en) * | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| LT2928489T (lt) * | 2012-12-05 | 2019-04-10 | Glaxosmithkline Biologicals S.A. | Imunogeninė kompozicija |
| CA2910200A1 (en) * | 2013-04-22 | 2014-10-30 | Board Of Regents Of The University Of Oklahoma | Clostridium difficile vaccine and methods of use |
| CA2976976C (en) | 2015-02-19 | 2023-02-28 | Immune Biosolutions Inc. | Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof |
| EP3810163A1 (en) * | 2018-06-19 | 2021-04-28 | GlaxoSmithKline Biologicals SA | Immunogenic composition |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| CZ296806B6 (cs) | 1994-10-24 | 2006-06-14 | Allergan, Inc. | Rozpustný fúzní protein a zpusob výroby rozpustného rekombinantního botulinového toxinu |
| JPH11509200A (ja) * | 1995-07-07 | 1999-08-17 | オラバックス インク． | 粘膜アジュバントとしてのクロストリジウム・ディフィシール（Ｃｌｏｓｔｒｉｄｉｕｍ Ｄｉｆｆｉｃｉｌｅ）トキシン |
| JP2002542169A (ja) * | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| EP1165796A2 (en) * | 1999-04-09 | 2002-01-02 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| AU2001251013A1 (en) | 2000-03-28 | 2001-10-08 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| WO2010017383A1 (en) * | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
| WO2011060431A2 (en) * | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
| KR101907434B1 (ko) | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
| GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
-
2012
- 2012-05-25 ES ES12726374.7T patent/ES2615737T3/es active Active
- 2012-05-25 PT PT16193340T patent/PT3138916T/pt unknown
- 2012-05-25 LT LTEP12724950.6T patent/LT2714910T/lt unknown
- 2012-05-25 SI SI201232050T patent/SI3564378T1/sl unknown
- 2012-05-25 US US14/122,690 patent/US9290565B2/en not_active Expired - Fee Related
- 2012-05-25 PT PT127249506T patent/PT2714910T/pt unknown
- 2012-05-25 HU HUE12726374A patent/HUE030823T2/en unknown
- 2012-05-25 MX MX2013013924A patent/MX346200B/es active IP Right Grant
- 2012-05-25 LT LTEP16193340.3T patent/LT3138916T/lt unknown
- 2012-05-25 BR BR112013030396A patent/BR112013030396A2/pt not_active IP Right Cessation
- 2012-05-25 PL PL12726374T patent/PL2714911T3/pl unknown
- 2012-05-25 RS RS20170051A patent/RS55605B1/sr unknown
- 2012-05-25 PT PT191798719T patent/PT3564378T/pt unknown
- 2012-05-25 FI FIEP19179871.9T patent/FI3564378T3/fi active
- 2012-05-25 ES ES19179871T patent/ES2968455T3/es active Active
- 2012-05-25 CA CA2837395A patent/CA2837395C/en active Active
- 2012-05-25 US US14/122,345 patent/US9409974B2/en active Active
- 2012-05-25 WO PCT/EP2012/059793 patent/WO2012163811A1/en active Application Filing
- 2012-05-25 HR HRP20231749TT patent/HRP20231749T1/hr unknown
- 2012-05-25 ME MEP-2017-26A patent/ME02600B/me unknown
- 2012-05-25 DK DK16193340.3T patent/DK3138916T3/da active
- 2012-05-25 PT PT127263747T patent/PT2714911T/pt unknown
- 2012-05-25 PL PL16193340T patent/PL3138916T3/pl unknown
- 2012-05-25 EP EP19179871.9A patent/EP3564378B1/en active Active
- 2012-05-25 LT LTEP12726374.7T patent/LT2714911T/lt unknown
- 2012-05-25 DK DK12724950.6T patent/DK2714910T3/en active
- 2012-05-25 KR KR1020137034795A patent/KR102014502B1/ko active IP Right Grant
- 2012-05-25 CA CA2837393A patent/CA2837393A1/en not_active Abandoned
- 2012-05-25 EP EP12726374.7A patent/EP2714911B1/en not_active Revoked
- 2012-05-25 CN CN201710239709.0A patent/CN107098977A/zh active Pending
- 2012-05-25 LT LTEP19179871.9T patent/LT3564378T/lt unknown
- 2012-05-25 DK DK12726374.7T patent/DK2714911T3/en active
- 2012-05-25 EP EP16193340.3A patent/EP3138916B1/en not_active Revoked
- 2012-05-25 CN CN201280037466.8A patent/CN103732750A/zh active Pending
- 2012-05-25 EP EP23205566.5A patent/EP4296361A3/en active Pending
- 2012-05-25 SI SI201231642T patent/SI3138916T1/sl unknown
- 2012-05-25 EA EA201391548A patent/EA030898B1/ru not_active IP Right Cessation
- 2012-05-25 JP JP2014511895A patent/JP2014516532A/ja active Pending
- 2012-05-25 CN CN201280037472.3A patent/CN103717742B/zh active Active
- 2012-05-25 ES ES16193340T patent/ES2743442T3/es active Active
- 2012-05-25 BR BR112013030395-6A patent/BR112013030395B1/pt active IP Right Grant
- 2012-05-25 PL PL19179871.9T patent/PL3564378T3/pl unknown
- 2012-05-25 PL PL12724950T patent/PL2714910T3/pl unknown
- 2012-05-25 ES ES12724950.6T patent/ES2660468T3/es active Active
- 2012-05-25 SG SG2013085386A patent/SG195037A1/en unknown
- 2012-05-25 DK DK19179871.9T patent/DK3564378T3/da active
- 2012-05-25 WO PCT/EP2012/059805 patent/WO2012163817A2/en active Application Filing
- 2012-05-25 HU HUE12724950A patent/HUE037126T2/hu unknown
- 2012-05-25 EP EP18150735.1A patent/EP3327126A1/en not_active Withdrawn
- 2012-05-25 SI SI201230868A patent/SI2714911T1/sl unknown
- 2012-05-25 HU HUE19179871A patent/HUE064492T2/hu unknown
- 2012-05-25 JP JP2014511899A patent/JP5952390B2/ja active Active
- 2012-05-25 SI SI201231247T patent/SI2714910T1/en unknown
- 2012-05-25 HU HUE16193340 patent/HUE044772T2/hu unknown
- 2012-05-25 EP EP12724950.6A patent/EP2714910B1/en active Active
- 2012-05-25 WO PCT/EP2012/059792 patent/WO2012163810A1/en active Application Filing
-
2013
- 2013-11-21 IL IL229529A patent/IL229529B2/en unknown
-
2016
- 2016-02-11 US US15/041,924 patent/US9644024B2/en active Active
- 2016-06-09 JP JP2016114910A patent/JP2017012160A/ja active Pending
- 2016-06-28 US US15/194,937 patent/US10093722B2/en active Active
-
2017
- 2017-01-20 HR HRP20170094TT patent/HRP20170094T1/hr unknown
- 2017-02-03 CY CY20171100158T patent/CY1118599T1/el unknown
- 2017-02-16 SM SM201700110T patent/SMT201700110B/it unknown
- 2017-03-21 US US15/464,454 patent/US10377816B2/en active Active
-
2018
- 2018-02-15 CY CY20181100188T patent/CY1119916T1/el unknown
- 2018-02-23 HR HRP20180339TT patent/HRP20180339T1/hr unknown
-
2019
- 2019-07-17 HR HRP20191291TT patent/HRP20191291T1/hr unknown
- 2019-08-27 CY CY20191100909T patent/CY1121936T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231749T1 (hr) | Imunogeni pripravak | |
| Mohn et al. | Immune responses after live attenuated influenza vaccination | |
| JP2017081939A5 (hr) | ||
| HRP20220717T1 (hr) | Modificirani pripravci mrna | |
| AR118560A2 (es) | Métodos y composiciones que comprenden polipéptidos recombinantes purificados | |
| HRP20161608T1 (hr) | Modificirani tuberkulozni antigeni | |
| HRP20171909T1 (hr) | Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe | |
| JP2014058541A5 (hr) | ||
| WO2019143949A3 (en) | Induce and enhance immune responses using recombinant replicon systems | |
| NZ630826A (en) | Anti-egfr antibody drug conjugate formulations | |
| ECSP11011278A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente. | |
| WO2011103453A3 (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
| BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| MY166282A (en) | Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses | |
| JP2011528896A5 (hr) | ||
| JP2015517488A5 (hr) | ||
| WO2014139476A8 (zh) | Rsv融合蛋白的表位以及识别其的抗体 | |
| HRP20230359T1 (hr) | Imunogeni pripravak | |
| BR112015018335A2 (pt) | Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas | |
| JP2011528895A5 (hr) | ||
| JP2010532766A5 (hr) | ||
| JP2016502551A5 (hr) | ||
| CL2012003458A1 (es) | Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico. | |
| EA033007B1 (ru) | ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ЛИПИДИРОВАННЫЙ ГЕТЕРОДИМЕР МУТАНТНЫХ ФРАГМЕНТОВ OspA, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ЕГО ПРИМЕНЕНИЯ |